Bausch Health Companies Inc. disclosed that its Phase 3 RED‑C program, a rifaximin solid‑soluble dispersion (SSD) designed to prevent the first episode of hepatic encephalopathy in patients with liver cirrhosis, did not meet its primary efficacy endpoint. The study enrolled more than 1,000 patients across 398 sites in 17 countries and reported that the drug was safe and well‑tolerated, but the predefined threshold for delaying encephalopathy was not achieved.
The failure removes a critical growth engine that Bausch Health had positioned as a successor to its flagship Xifaxan, whose patent protection is expected to expire around 2028. With Xifaxan’s revenue already accounting for a sizable share of the company’s hepatology portfolio, the loss of a potential $2 billion‑plus peak revenue stream deepens the pressure on the firm’s ability to service its roughly $21 billion of long‑term debt and to pursue the planned separation of the profitable Bausch + Lomb unit.
CEO Thomas Appio said the company was disappointed but would review the full dataset to identify new development opportunities. CFO Jean‑Jacques Charhon noted that the company’s operating expenses had been unusually low in the most recent quarter due to non‑recurring accrual adjustments, suggesting that cost normalization is underway as the firm focuses on its core assets.
In Q3 2025, Bausch Health reported consolidated revenue of $2.68 billion, up 7 % year‑over‑year, with Xifaxan sales growing 16 % and contributing a significant portion of the top line. The company’s high interest expense of $397 million in that quarter underscored the financial strain that a successful RED‑C program could have alleviated. Management has not yet revised its full‑year guidance, but the trial outcome signals a potential shift in the company’s growth trajectory.
Investors reacted negatively to the news, reflecting concerns about the company’s ability to replace Xifaxan’s revenue stream and to manage its debt load. The market’s response underscores the importance of the RED‑C program to Bausch Health’s long‑term strategy and highlights the broader headwinds the firm faces as it navigates a competitive hepatology landscape and a looming patent cliff.
The RED‑C setback illustrates the high risk of late‑stage drug development and the strategic vulnerability of a portfolio heavily reliant on a single blockbuster. Bausch Health’s next steps will likely involve accelerating alternative pipeline candidates, reassessing its capital allocation, and exploring options to reduce debt and unlock value from its Bausch + Lomb unit.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.